SCHEMBL20580700

SCHEMBL20580700

CC(C)(C)C(=O)N1OCC[C@@H]1c1cccc(F)c1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 7/20 0.64
PDE5A O76074 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
KIF11 P52732 3/20 0.40
KCNH2 Q12809 1/20 0.39
JAK2 O60674 1/20 0.38
NTRK1 P04629 1/20 0.38
DRD4 P21917 1/20 0.37
KCNQ2 O43526 1/20 0.37
PIK3C3 Q8NEB9 2/20 0.37
MAOB P27338 1/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22210923 1.00 RIPK1 (0.64) RIPK1PDE5AKDM4EALDH1A1PKM
SCHEMBL18921372 1.00 RIPK1 (0.64) RIPK1PDE5AKDM4EALDH1A1PKM
SCHEMBL20580146 0.87 RIPK1 (0.52) RIPK1KIF11
SCHEMBL18921329 0.87 RIPK1 (0.52) RIPK1KIF11
SCHEMBL18921362 0.87 RIPK1 (0.52) RIPK1KIF11
SCHEMBL22232775 0.84 RIPK1 (0.54) RIPK1PDE5AKDM4EALDH1A1PKM
SCHEMBL29641347 0.84 RIPK1 (0.54) RIPK1PDE5AKDM4EALDH1A1PKM
SCHEMBL29641499 0.84 RIPK1 (0.54) RIPK1PDE5AKDM4EALDH1A1PKM
SCHEMBL22232784 0.84 RIPK1 (0.54) RIPK1PDE5AKDM4EALDH1A1PKM
SCHEMBL18921457 0.84 RIPK1 (0.54) RIPK1PDE5AKDM4EALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10709692-B2 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) DENALI THERAPEUTICS INC. (US) 2020-07-14 US disclosed
US-10709692-B2 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) DENALI THERAPEUTICS INC. (US) 2020-07-14 US disclosed
US-20180353480-A1 ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) APTUIT (VERONA) S.R.L. (IT) 2018-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180353480-A1 ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) RIPK1, RIPK2, RIPK3 RIPK1 1/4885PDE5A 3792/4885KDM4E 4151/4885
US-10709692-B2 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) RIPK1, RIPK2, RIPK3 RIPK1 1/4885PDE5A 3792/4885KDM4E 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.